BiotechTube
Biointron

Biointron

Cambridge, United States· Est.
biointron.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $7.8M

Overview

Biointron is a specialized CRO providing end-to-end antibody development services, from discovery through large-scale production. Its core value proposition is speed, cost-effectiveness, and high-throughput capabilities, leveraging automated platforms to serve over 3,000 global biopharma clients. The company holds a unique asset in its commercial licensing rights for the CHO-K1BN cell line and has established credibility through testimonials from major pharmaceutical firms. As a private, service-oriented business, its growth is tied to the expanding outsourced antibody R&D market.

Antibodies

Technology Platform

High-throughput, automated platforms for antibody discovery (AbDrop), production, and optimization. Proprietary commercial license for CHO-K1BN cell line for stable cell line generation and protein expression.

Funding History

2
Total raised:$7.8M
Seed$2.8M
Seed$5M

Opportunities

The expanding global market for antibody therapeutics and complex biologics drives demand for outsourced, high-speed discovery and production services.
The company's exclusive rights to commercialize the CHO-K1BN cell line provide a unique asset for licensing revenue and attracting clients needing stable cell lines.
Growth can be achieved by expanding service offerings, entering new geographic markets, and deepening partnerships with the 3,000+ biopharma companies it already serves.

Risk Factors

Intense competition from numerous established and emerging CROs could pressure pricing and market share.
The business model lacks therapeutic asset ownership, capping financial upside relative to drug developers.
Operational risks include maintaining quality and speed at scale, and reputation damage from service failures.

Competitive Landscape

Biointron competes in a fragmented CRO market against large, full-service CROs (e.g., Charles River, LabCorp) and numerous specialized antibody service providers. Its differentiation is based on high-throughput automation, rapid turnaround times (e.g., 2-week antibody expression), and cost-effectiveness. The exclusive CHO-K1BN cell line license provides a competitive moat in stable cell line development.

More companies in Biologics / Biosimilars →More companies in United States →